ReviewAnnals of clinical microbiology and antimicrobials2020
Microbiota in vaginal health and pathogenesis of recurrent vulvovaginal infections: a critical review.
Review in Annals of clinical microbiology and antimicrobials, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 121 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
121 citing papers in PubMed.
- Trial
- Relieving effect of Lactobacillus crispatus RS08 on Candida albicans-induced vaginitis by regulating NF-κB signaling pathway.Antonie van Leeuwenhoek · 2026Article
- Rethinking Vaginal Microbiome Resilience: A Conceptual Multi-Omic Framework.Microorganisms · 2026Review
- Vaginal microbiomes and their pertinent social context: a microbial ecological review proffering AMR-STI acquisition and emergence.Biology of sex differences · 2026Review
- Dynamic, transition and variation of cervicovaginal microbiome and HPV infection and cervical dysplasia and cancer: a systematic review.Infectious agents and cancer · 2026Review
- Saccharomyces cerevisiae reduces vulvovaginal candidiasis severity through modulation of fungal pathogenicity and inflammatory responses.Nature communications · 2026Article
- Understanding The Role of Lacticaseibacillus rhamnosus in Vaginal Dysbiosis: in Vitro Studies and Clinical Evidence.Probiotics and antimicrobial proteins · 2026Review
- Intratumoral microbiota in cancer: molecular mechanism and therapeutic strategies.Molecular biomedicine · 2026Review
- Vaginal microbiome and inflammation cytokines among Chinese women.NPJ biofilms and microbiomes · 2026Article
- Comprehensive Evaluation of a Mucoadhesive Self-Emulsifying Anhydrous Base for Vaginal Drug Delivery.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Characterization of the vaginal microbiome and its metabolic potential in Colombian patients with recurrent vulvovaginal candidiasis.Medical mycology · 2026Article
- Research Progress in the Treatment of Vaginitis With Bioactive Compounds: Targeting of Vaginal Microflora.MicrobiologyOpen · 2026Review
- Microbiota Transplantation as a Future Novel Therapeutic Strategy Approach.Diseases (Basel, Switzerland) · 2026Review
- Predictive modeling for cervical cancer: existing AI approaches and the emerging role of vaginal microbiome.Frontiers in network physiology · 2026Article
- Beyond community state types: vaginal microbial diversity and CST-IV signatures are associated with pregnancy in euploid embryo transfer cycles.Frontiers in endocrinology · 2026Article
- The interventional value and research progress of vaginal microbiota transplantation in improving female sexual quality of life associated with dysbiosis of the reproductive microecosystem.Frontiers in medicine · 2026Review
- Could diet and body composition influence vaginitis treatment success? A clinical nutrition-based analysis.Frontiers in nutrition · 2026Article
- Progress in interventions for vaginal microecology.Frontiers in cellular and infection microbiology · 2026Review
- Longitudinal Analysis of Vulvovaginal Bacteriome Following Use of Water- and Silicone-Based Personal Lubricants: Stability, Spatial Specificity, and Clinical Implications.Microorganisms · 2025Article
- New Strategies for Preventing Perinatal Group B Streptococcus (GBS) Infections.Pathogens (Basel, Switzerland) · 2025Review
61 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recurrent vulvovaginal infections (RVVI) has not only become an epidemiological and clinical problem but also include large social and psychological consequences. Understanding the mechanisms of both commensalism and pathogenesis are necessary for the development of efficient diagnosis and treatment strategies for these enigmatic vaginal infections. Through this review, an attempt has been made to analyze vaginal microbiota (VMB) from scratch and to provide an update on its current understanding in relation to health and common RVVI i.e. bacterial vaginosis, vulvovaginal candidiaisis and Trichomoniasis, making the present review first of its kind. For this, potentially relevant studies were retrieved from data sources and critical analysis of the literature was made. Though, culture-independent methods have greatly unfolded the mystery regarding vaginal bacterial microbiome, there are only a few studies regarding the composition and diversity of vaginal mycobiome and different Trichomonas vaginalis strains. This scenario suggests a need of further studies based on comparative genomics of RVVI pathogens to improve our perceptive of RVVI pathogenesis that is still not clear (Fig. 5). Besides this, the review details the rationale for Lactobacilli dominance and changes that occur in healthy VMB throughout a women's life. Moreover, the list of possible agents continues to expand and new species recognised in both health and VVI are updated in this review. The review concludes with the controversies challenging the widely accepted dogma i.e. "VMB dominated with Lactobacilli is healthier than a diverse VMB". These controversies, over the past decade, have complicated the definition of vaginal health and vaginal infections with no definite conclusion. Thus, further studies on newly recognised microbial agents may reveal answers to these controversies. Conversely, VMB of women could be an answer but it is not enough to just look at the microbiology. We have to look at the woman itself, as VMB which is fine for one woman may be troublesome for others. These differences in women's response to the same VMB may be determined by a permutation of behavioural, cultural, genetic and various other anonymous factors, exploration of which may lead to proper definition of vaginal health and disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.